Oral Antipsychotic Medications for Acute Psychosis
For acute psychosis, start with oral risperidone 2 mg/day or olanzapine 7.5-10 mg/day as first-line treatment, as these atypical antipsychotics are equally effective to conventional agents but significantly better tolerated with fewer extrapyramidal side effects. 1
First-Line Oral Agents
The international clinical practice guidelines for early psychosis establish clear initial target doses 1:
- Risperidone: 2 mg/day (can increase to maximum 4 mg/day in first-episode psychosis)
- Olanzapine: 7.5-10 mg/day (can increase to maximum 20 mg/day)
These atypical antipsychotics should be prioritized because although typical antipsychotics may be equally efficacious in reducing positive psychotic symptoms, they are less well tolerated even at low doses 1. The improved tolerability directly impacts future medication adherence, which is critical for long-term outcomes.
Alternative Oral Atypical Antipsychotics
Additional oral options with established efficacy include 2, 3:
- Quetiapine: Start 12.5 mg twice daily (more sedating; maximum 200 mg twice daily)
- Aripiprazole: 5 mg daily (lower risk of metabolic and prolactin effects)
- Chlorpromazine: 12.5-25 mg (sedating, anticholinergic effects)
Conventional Antipsychotics (Second-Line)
If atypical agents are unavailable or not tolerated 1:
- Haloperidol: Maximum 4-6 mg/day in first-episode psychosis (higher extrapyramidal symptom risk)
Critical caveat: Extrapyramidal side-effects should be avoided to encourage future adherence 1. The guidelines explicitly state this is a priority even though conventional agents may have similar efficacy for positive symptoms.
Combination Therapy for Acute Agitation
When acute psychosis presents with severe agitation, oral risperidone 2 mg plus oral lorazepam 2 mg is as effective as intramuscular conventional treatment and causes fewer extrapyramidal symptoms 4, 5. This combination:
- Achieves treatment success (asleep or much improved) in 66.9% at 2 hours 4
- Produces significant improvement at 30,60, and 120 minutes 5
- Results in only 1.7% extrapyramidal symptoms versus 9.5% with IM conventional agents 4
Dosing Strategy
Start low and increase slowly 1:
- After initial titration, increase doses only at 14-21 day intervals if response is inadequate
- Increase only within limits of sedation and emergence of extrapyramidal side-effects
- Low doses will not have rapid effect on all symptoms, but this approach prioritizes long-term adherence
Treatment-Resistant Cases
If positive psychotic symptoms persist after trials of two first-line atypical antipsychotics (around 12 weeks each), switch to clozapine 6. Clozapine is specifically recommended for treatment-resistant schizophrenia with the strongest evidence (1B recommendation).
Key Clinical Pitfalls to Avoid
Do not use high-potency typical antipsychotics as first-line: Despite their efficacy, the extrapyramidal side effects significantly impair adherence and quality of life 1
Avoid anticholinergic agents prophylactically in most patients: Only consider in those at high risk for acute dystonias or with history of dystonic reactions 7
Do not combine benzodiazepines with high-dose olanzapine: Fatalities have been reported with this combination 3
Monitor for reversible causes first: Before escalating antipsychotic doses, ensure you've addressed hypoxia, urinary retention, constipation, and substance intoxication 8, 9
Practical Algorithm
- First choice: Risperidone 2 mg/day OR olanzapine 7.5-10 mg/day
- If agitated: Add lorazepam 0.5-2 mg (can use oral tablets sublingually)
- If inadequate response at 14-21 days: Increase dose within tolerance limits
- If fails after 12 weeks: Switch to second atypical antipsychotic
- If two atypical agents fail: Switch to clozapine
The evidence strongly supports oral atypical antipsychotics as first-line treatment, with the combination of efficacy and tolerability being the determining factor for long-term outcomes in acute psychosis 1, 6, 4, 5.